Our surveillance was performed for 358 patients with locally advanced TIG Torch Alumina Cup and disseminated prostate gland cancer who were treated by analogues of LHRH.Patients in group 1 (n = 222) received treatment with a LHRH analogue, and patients in group 2 (n = 136) received treatment with 75 mg Buserelin-depo 3.Experience has shown that the use of the Buserelin-Depot drug results in a regression of the average PSA value: Up to 36.
05 ng/ml in 2 months, up to 12.35 ng/ml - in four months, up to 3.3 ng/ml - in six months.
The drug ensures a steady decrease in the level of testosterone in the blood serum to the castration level already in a month after the start of treatment, a decrease in prostate gland volume (from 57.3 to 40.45 cc 3 by month 6 of treatment Eternal Ink Liz Cook Portrait Series (-29.
4%)).A number of patients have experienced a decrease in the need for analgesics and thus an increase in the activity status.The obtained data are comparable to those in the group of patients receiving other analogues of LHRH.